Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 5Leukemia, Myeloid, Acute 5Leukemia, Myelomonocytic, Chronic 3Solid Tumor 1Melanoma 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Diseases 1Cytopenia 1Anemia, Refractory, with Excess of Blasts 1

Interventions

thymoglobulin 1fludarabine phosphate 1fludarabine 1decitabine and cedazuridine drug combination 1cedazuridine 1Therapeutics 1Specimen Handling 1Pluvicto 1Peripheral Blood Stem Cell Transplantation 1Interleukin-8 1HuMax-IL8 1Granulocyte Colony-Stimulating Factor 1Genetic Counseling 1Filgrastim 1Exercise 1Emapalumab 1Decitabine 1DNA 1Cyclophosphamide 1Busulfan 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytopenia × cedazuridine × 1 year × Clear all
NCT05148234 2025-09-30

BMS-986253 in Myelodysplastic Syndromes

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
2 enrolled 11 charts
Classical hematologyMyeloid

Cytopenia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡